Neurocrine Biosciences (NBIX) Gross Profit (2017 - 2026)

Neurocrine Biosciences (NBIX) has reported Gross Profit for 10 consecutive years, with $935.8 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Gross Profit rose 38.19% year-over-year to $935.8 million; the trailing twelve-month figure through Jun 2026 stood at $3.3 billion (up 33.65% YoY), and the FY2025 full-year result was $2.8 billion, up 20.98% from the prior year.
• Gross Profit climbed to $935.8 million in Q2 2026 per NBIX's latest filing, from $800.7 million in the prior quarter.
• Across five years, Gross Profit topped out at $935.8 million in Q2 2026 and bottomed at $306.0 million in Q1 2022.
• Historically, Gross Profit has averaged $565.6 million across 5 years, with a median of $535.6 million in 2024.
• The sharpest annual moves came in 2025 and 2026: Gross Profit increased 10.95% in 2025, then surged 42.12% in 2026.
• Over 5 years, Gross Profit stood at $404.3 million in 2022, then climbed by 25.33% to $506.7 million in 2023, then grew by 22.04% to $618.4 million in 2024, then grew by 27.41% to $787.9 million in 2025, then rose by 18.77% to $935.8 million in 2026.
• According to Business Quant data, Gross Profit over the past three periods registered $935.8 million, $800.7 million, and $787.9 million for Q2 2026, Q1 2026, and Q4 2025 respectively.